pain (likert) msd  (Pfizer Inc)

Journal: The Journal of rheumatology

Article Title: Application of the OMERACT filter to measures of core outcome domains in recent clinical studies of acute gout

doi: 10.3899/jrheum.131245

Figure Lengend Snippet: Indices of test-retest reliability, smallest detectable difference and minimal important difference

Article Snippet: Significant floor effects were appreciable at final visit (47 to 64%) and ceiling effects (27 to 56%) were appreciable at baseline. table ft1 table-wrap mode="anchored" t5 caption a7 ICC SEM SDD MID Pain (Likert) MSD Between day 2 and 5 0.56 0.51 1.41 1 Between day 5 and 8 0.80 0.42 1.17 2 Pfizer * Between 2 and 4 hours 0.81 0.39 1.08 -- Between 2 and 8 hours 0.72 0.50 1.39 -- Between 2 and 12 hours 0.60 0.62 1.72 -- Pfizer † Between day 1 and 9 0.07 0.76 2.1 2 Between day 2 and 9 0.15 0.76 2.1 2 Between day 5 and 9 0.59 0.54 1.50 2 Novartis Baseline to 7 days post dose 0.35 0.85 2.36 1.0 24 hours post dose to 7 days 0.55 0.64 1.77 -- 48 hours post dose to 7 days 0.71 0.49 1.36 -- Pain (VAS) Novartis Baseline to 7 days post dose 0.35 3.66 10.15 19 24 hours post dose to 7 days 0.57 2.93 8.12 -- 48 hours post dose to 7 days 0.76 2.23 6.18 -- Joint tenderness MSD Between day 2 and day 5 0.50 0.46 1.28 2 Between day 5 and day 8 0.79 0.34 0.94 1 Pfizer Between Day 1 and 9 0.06 0.66 1.8 2 Between Day 5 and 9 0.11 0.59 1.6 2 Novartis Baseline to 7 days Post 0.0 ** 1.06 2.93 1.0 24 hours post dose to 7 days 0.50 0.54 1.51 -- 48 hours post dose to 7 days 0.49 0.54 1.50 -- 72 hours post dose to 7 days 0.49 0.54 1.50 -- Joint swelling MSD Between day 2 and day 5 0.48 0.53 1.47 1 Between day 5 and day 8 0.77 0.43 1.18 1 Pfizer Between Day 1 and 9 0.13 0.64 1.8 1 Between Day 5 and 9 0.37 0.73 2.0 1 Novartis Baseline to 7 days 0.0 1.07 2.97 1 24 hours post dose to 7 days 0.44 0.65 1.80 -- 48 hours post dose to 7 days 0.44 0.65 1.79 -- 72 hours post dose to 7 days 0.44 0.65 1.79 -- Activity limitations Novartis 0.55 0.45 1.25 0.5 Open in a separate window * Pain assessed as ‘current’ level of pain † Pain assessed as ‘over the last 24 hours’ ** Statistical software indicated that estimation of a negative variance parameter was attempted Indices of test-retest reliability, smallest detectable difference and minimal important difference

Techniques: Activity Assay